Moderna has teamed up with OpenAI to integrate ChatGPT Enterprise across its operations, enhancing productivity and innovation among its workforce. The biotechnology firm, known for its mRNA medicines like the COVID-19 vaccine, aims to bring a new wave of treatments to market by leveraging advanced technology. This move signifies a strategic shift towards a more efficient, AI-empowered approach to drug development and corporate functions.
In the rapidly evolving biopharmaceutical industry, staying ahead requires constant innovation and the ability to quickly adapt to new technologies. Moderna recognized the need for a comprehensive digital transformation to maintain its competitive edge and accelerate its research and development efforts. By embracing generative AI, the company seeks to streamline processes, from legal documentation to clinical trial analysis, thereby enhancing overall efficiency and decision-making capabilities.
Moderna’s implementation of ChatGPT Enterprise and the development of custom GPTs, such as Dose ID for clinical data analysis and Contract Companion for legal summaries, exemplify the solution. These initiatives have not only improved operational efficiency but also fostered a culture of continuous learning and innovation. The result is a more agile organization that can achieve significant advancements in medicine with a leaner team, demonstrating the tangible benefits of integrating generative AI into the core of business strategies.
Outcomes:
- Developed 750 tailored GPT models company-wide in 60 days.
- Weekly, 40% of active users designed personal GPTs.
- The average user engages in 120 ChatGPT dialogues weekly (3 every hour).
AI Tools Created:
- Policy Bot: Instant company policy clarifications.
- Dose ID: Clinical data scrutiny for vaccine dosing.
- Contract Companion: Summarizes legal documents succinctly.
- Earnings Prep Assistant: Creates investor presentation slides.
- Brand Storyteller: Customizes messaging for diverse markets.
Why Should You Care?
The partnership between Moderna and OpenAI to deploy ChatGPT Enterprise is significant for technology leaders because:
– AI empowers every function in Moderna, creating innovative use cases.
– Moderna’s adoption of generative AI transforms business processes and increases human capacity.
– The workforce is successfully transformed through individual, collective, and structural change management initiatives.
– ChatGPT Enterprise has been widely adopted, with high satisfaction among employees.
– GPTs built across the company have improved clinical trial development, compliance, and storytelling.
– AI enables Moderna to achieve ambitious goals with a lean team, setting new benchmarks in innovation.
– The use of AI ultimately translates to better outcomes for patients.